Get the Stockscreener App
178.08
6.34%
-12.06
Pre-market:
176.63
-1.45
-0.81%
Charles River Laboratories International Inc stock is traded at $178.08, with a volume of 1.86M.
It is down -6.34% in the last 24 hours and down -6.50% over the past month.
See More
Previous Close:
$190.14
Open:
$179.87
24h Volume:
1.86M
Relative Volume:
2.80
Market Cap:
$9.72B
Revenue:
$4.06B
Net Income/Loss:
$413.08M
P/E Ratio:
22.23
EPS:
8.01
Net Cash Flow:
$560.48M
1W Performance:
-6.16%
1M Performance:
-6.50%
6M Performance:
-17.63%
1Y Performance:
-15.80%
1-Day Range:
$175.61
$185.00
1-Week Range:
$175.61
$190.68
52-Week Range:
$175.61
$275.00
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
178.08 | 9.72B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
556.99 | 213.05B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
237.62 | 171.63B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
143.43 | 40.54B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.96 | 35.93B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
418.63 | 34.28B | 3.84B | 866.24M | 792.60M | 10.37 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Charles River Laboratories International (NYSE:CRL) Reaches New 1-Year LowHere's Why - MarketBeat
Citi flags revenue and margin headwinds for Charles River Labs shares By Investing.com - Investing.com South Africa
Charles River Laboratories International's (CRL) "Outperform" Rating Reiterated at William Blair - MarketBeat
TD Cowen cautious on Charles River Labs stock as 2025 guide signals further declines - Investing.com India
JPMorgan maintains Charles River Labs stock at Neutral on challenges - Investing.com India
Citi flags revenue and margin headwinds for Charles River Labs shares - Investing.com India
Charles River Laboratories International (NYSE:CRL) Shares Gap DownWhat's Next? - MarketBeat
JPMorgan maintains Charles River Labs stock at Neutral on challenges By Investing.com - Investing.com Nigeria
Clinical Trials Support Services Market Poised for Notable Expansion by 2030, Driven by Substantial Investments in R&D from Pharmaceutical and Biopharmaceutical Companies - GlobeNewswire Inc.
Charles River Laboratories (CRL) Provides Preliminary 2025 Finan - GuruFocus.com
Charles River Labs stock hits 52-week low at $176.34 - Investing.com India
BofA keeps Charles River Labs stock at Neutral on challenges By Investing.com - Investing.com UK
Charles River stock falls on 2025 revenue drop (CRL:NYSE) - Seeking Alpha
Charles River Labs Discusses 2025 Financial Outlook - TipRanks
Charles River Laboratories stock falls on weak 2025 revenue outlook By Investing.com - Investing.com UK
Bioanalytical Testing Services Market Size, Embracing Growth - openPR
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Reinhart Partners LLC. Sells 11,822 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference - sharewise
Charles River Labs to Present Strategic Overview at J.P. Morgan Healthcare Conference - StockTitan
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Recommendation of "Reduce" from Analysts - MarketBeat
First Hawaiian Bank Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You - Simply Wall St
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Deciphex Secures $32.3M Series C to Transform AI-Powered Pathology Diagnosis - StockTitan
Preclinical Medical Device Testing Services Market Outlook, - GlobeNewswire
Preclinical Medical Device Testing Services Market Outlook, 2025-2035Dominated by Charles River Laboratories Int'l, Eurofins Scientific, SGS, WuXi AppTec, and Pace Analytical Services - Yahoo Finance
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Should You Retain Charles River Stock in Your Portfolio Now? - MSN
CHARLES RIVER LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Ag - AccessWire
Charles River Laboratories Stock: Is CRL Underperforming the Healthcare Sector? - MSN
Charles River Laboratories Stock: Is CRL Underperforming The Healthcare Sector? - Barchart
Zacks Research Issues Negative Forecast for CRL Earnings - MarketBeat
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Declining Stock and Solid Fundamentals: Is The Market Wrong About Charles River Laboratories International, Inc. (NYSE:CRL)? - Simply Wall St
RNA Therapy Clinical Trials Market Top Companies StudyIQVIA; - openPR
Charles River Laboratories International Inc. stock rises Tuesday, still underperforms market - MarketWatch
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Interesting CRL Put And Call Options For August 2025 - Nasdaq
Earnings are growing at Charles River Laboratories International (NYSE:CRL) but shareholders still don't like its prospects - Yahoo Finance
Charles River Laboratories International, Inc. (NYSE:CRL) Receives $214.00 Average Price Target from Brokerages - MarketBeat
Bioanalytical Services Market Key Players AnalysisPPD, Inc., - openPR
Sanctuary Advisors LLC Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Lord Abbett & CO. LLC Acquires 5,959 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Cell Line Development Market Top PlayersBiovian, Charles River Laboratories, Creative Biogene, KBI Biopharma. - openPR
CRL Stock to Gain From the Global Biotech Incubator Program Launch - MSN
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):